Showing 7951-7960 of 8696 results for "".
- Skin Cancer Foundation: Champions for Change Gala Raises $600,000https://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-raises-600000/2457527/The Skin Cancer Foundation’s 22nd annual Gala raised $600,000 to support the organization’s educational campaigns, community programs, and research initiatives. More than 400 guests attended the event, including Skin Cancer Foundation donors, industry and physician allies, celebrity s
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab
- Pennsylvania Passes SUNucate, Allowing Sunscreen Use and Protective Clothing at Schoolhttps://practicaldermatology.com/news/pennsylvania-passes-sunucate-allowing-sunscreen-use-and-protective-clothing-at-school/2457529/Pennsylvania became the 17th state to allow children to possess and apply sunscreen at school. Governor Tom Wolf approved HB 1228, a piece of legislation based on American Society for Dermatologic Surgery Association’s (ASDA) model bill known as SUNucate<
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel
- Krystal Biotech: Positive Interim Results in Phase 1/2 Trial of KB103https://practicaldermatology.com/news/krystal-biotech-positive-interim-results-in-phase-12-kb103-trial/2457562/
- Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acnehttps://practicaldermatology.com/news/study-positive-results-for-ortho-dermatologics-altrenos-safety-and-tolerability-for-acne/2457569/Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topi
- ASDS Announces 2018 President's Award Recipientshttps://practicaldermatology.com/news/asds-announces-2018-presidents-award-recipients/2457565/In her final act as president this week, Lisa M. Donofrio, MD, recognizes four members of the American Society for Dermatologic Surgery (ASDS) with the President’s Award at the Society’s Annual Meeting. “One of the wonderful gifts about being president of an organization
- Scar-Less Healing May be on the Horizonhttps://practicaldermatology.com/news/scar-less-healing-may-be-on-the-horizon/2457595/Stromal cell-derived-factor-1 (SDF1), a compound secreted in the bloodstream, may be the key factor that causes wounds in older people to heal with less scarring than in younger people, according to researchers from the Perelman School of Medicine at the Univer
- Celebrity Manicurist Joins with Galderma for "Face Your Hands" Campaignhttps://practicaldermatology.com/news/celebrity-manicurist-deborah-lippmann-joins-with-galderma-for-face-your-hands-campaign/2457596/Galderma Laboratories, L.P.,’s Restylane® Lyft is partnering with celebrity manicurist Deborah Lippmann for the "Face Your Hands" campaign, which aims to educate women on the steps they can take to achieve more youthful hands. A
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is